The (F)low Down on the Endothelial Epithelial Sodium Channel

Epithelial Sodium Channel as a Brake on Flow-Mediated Vasodilation

Heather A. Drummond

The epithelial sodium channel (ENaC) contributes to blood pressure homeostasis through renal salt and water transport; increases in ENaC activity increase salt and water reabsorption along the distal nephron, increasing extracellular fluid volume and blood pressure. The importance of tubular ENaC in cardiovascular homeostasis is manifested in Liddle’s disease and type I pseudohypaldosteronism, diseases associated with the gain and loss of ENaC function, respectively. However, several recent studies suggest that ENaC proteins may play a more ubiquitous role in blood pressure control as mechanosensors. Because ENaC proteins are closely related to a family of mechanosensitive proteins in the nematode termed “degenerins,” several laboratories have addressed the potential role of ENaC proteins as mechanosensors. In addition to their role in salt and water homeostasis, ENaC proteins and their relatives, acid-sensing ion channels (ASICs), may contribute to control of blood pressure through reflex regulation of the autonomic nervous system (baroreflex, chemoreflex, and metaboreflex) and local control of vascular tone. Recent literature reviews suggest that ENaC proteins may function as sensors of pressure-induced vascular stretch and laminar flow. The role of ENaC as a mediator of pressure-induced constriction in certain vessels is supported by several investigations; however, the role of ENaC as a flow sensor remains unclear.

ENaC as an Endothelial Flow Sensor

Because of their evolutionary relationship to mechanotransduction in the nematode, several laboratories have suggested that ENaC channels may act as flow sensors. Several lines of evidence suggest that ENaC channels are activated by flow. First, increases in laminar flow increase ENaC-dependent Na\(^+\) transport in the distal collecting duct. Second, laminar flow increases ENaC whole-cell current and channel open probability in oocytes expressing ENaC channels. Third, laminar flow increases the open-probability ENaC channels in endothelial cells. These studies suggest that ENaC activity can be regulated by laminar flow and, thus, that ENaC channels are candidates for transducing shear force in endothelial cells; however, the functional significance of ENaC in flow-mediated vascular reactivity is not clear.

The current report by Pérez et al\(^6\) demonstrates that ENaC expression in mesenteric endothelial cells regulates vascular tone. ENaC inhibition with amiloride (0.5 \(\mu\)mol/L) and benzamil (1 \(\mu\)mol/L) blunts agonist-induced vasoconstriction in an NO-dependent manner and increases NO production, a finding that suggests that basal ENaC activity in endothelial cells maintains vasoconstrictor reactivity by suppressing NO production (Figure ). Furthermore, ENaC inhibition enhanced flow-mediated vasodilation, demonstrated by a upward shift of the flow-diameter relationship (Figure 7C in Reference 5), suggesting that basal-level ENaC activity acts as a brake on flow-mediated vasodilation in mesenteric arteries (resting diameter: \(\approx 200 \mu\)m). The findings by Pérez et al\(^6\) demonstrate a functional role for endothelial ENaC in flow-mediated dilation but suggest that endothelial ENaC negatively modulates, but does not mediate, flow-mediated dilation in the mesenteric circulation.

Interpreting the importance of ENaC channels in this study is heavily dependent on the specificity of amiloride and its analogs. Although amiloride can block other channels and transporters, eg, voltage-gated Ca\(^{2+}\) and Na\(^+\) channels, Na\(^+\)/H\(^+\) transporter, or the Na\(^+\)/Ca\(^{2+}\) exchanger, amiloride can be highly selective for ENaC. The caveat is that the concentration must be submicromolar or very low micromolar. The study by Pérez et al\(^5\) used a submicromolar concentration of 0.5 \(\mu\)mol/L. Pérez et al\(^5\) also found a similar effect of benzamil, a lipophilic amiloride analog with increased selectivity for ENaC, and a lack of effect of ethyl isopropyl amiloride (0.5 \(\mu\)mol/L; Figure S2 in Reference 5), an amiloride analog selective for the Na\(^+\)/H\(^+\) transporter. Thus, as far as we know, the doses of amiloride and benzamil used in the study by Pérez et al\(^5\) are relatively specific for ENaC. However, because there is no “silver bullet,” and lingering doubt regarding the amiloride specificity remains, future studies using alternative methods to inhibit ENaC expression, eg, transient gene silencing, and genetically modified animals are needed to confirm the results of Pérez et al.\(^5\)

Although the findings of Pérez et al\(^5\) suggest that ENaC is probably not a flow sensor in mesenteric arteries, a direct role for ENaC as a mediator of flow-induced dilation in other circulatory beds cannot be ruled out. Heterogeneity in signaling mechanisms in vessels of different sizes and locations is common, particularly as it relates to the role of ENaC in vascular smooth muscle cells in mesenteric, renal, and cere-
sensory hypothesis, the role of ENaC proteins as endothelial flow sensors should be evaluated further using multiple approaches, including in vitro and whole-animal approaches in genetically modified animals.

An important finding of Pérez et al is that this study provides evidence that the endothelial ENaC channels are active and participate in flow-induced dilation. Future studies are needed to define the role of ENaC channels as shear stress sensors in endothelial cells in mesenteric and other circulatory beds.

**Source of Funding**

This work was supported by National Heart, Lung, and Blood Institute grant HL086996.

**Disclosures**

None.

**References**


The (F)low Down on the Endothelial Epithelial Sodium Channel: Epithelial Sodium Channel as a Brake on Flow-Mediated Vasodilation
Heather A. Drummond

Hypertension. 2009;53:903-904; originally published online April 27, 2009;
doi: 10.1161/HYPERTENSIONAHA.109.128868

Hypertension is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2009 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/53/6/903

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Hypertension can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Hypertension is online at:
http://hyper.ahajournals.org//subscriptions/